Search

Your search keyword '"Wu, Jaw-Ching"' showing total 930 results
Start Over Author "Wu, Jaw-Ching"
930 results on '"Wu, Jaw-Ching"'

3. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Pan, Calvin, Jia, Jidong, Berg, Thomas, Gray, Richard, Lim, Young-Suk, Chen, Chien-Jen, Ocama, Ponsiano, Desalegn, Hailemichael, Abbas, Zaigham, Abdallah, Ayat, Aghemo, Alessio, Ahmadbekova, Sabohat, Ahn, Sang Hoon, Aho, Inka, Akarca, Ulus, Al Masri, Nasser, Alalwan, Abduljaleel, Alavian, Seyed, Al-Busafi, Said, Aleman, Soo, Alfaleh, Faleh, Alghamdi, Abdullah, Al-Hamoudi, Waleed, Aljumah, Abdulrahman, Al-Naamani, Khalid, Al-Rifai, Ahmad, Alserkal, Yousif, Altraif, Ibrahim, Amarsanaa, Jazag, Anderson, Motswedi, Andersson, Monique, Armstrong, Paige, Asselah, Tarik, Athanasakis, Kostas, Baatarkhuu, Oidov, Ben-Ari, Ziv, Bensalem, Aicha, Bessone, Fernando, Biondi, Mia, Bizri, Abdul Rahman, Blach, Sarah, Braga, Wornei, Brandão-Mello, Carlos, Brosgart, Carol, Brown, Kimberly, Brown, Jr, Robert, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Cabezas, Joaquin, Casanovas, Teresa, Chae, Chungman, Chan, Henry Lik Yuen, Cheinquer, Hugo, Chen, Pei-Jer, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Coffin, Carla, Contreras, Fernando, Coppola, Nicola, Cornberg, Markus, Cowie, Benjamin, Cramp, Matthew, Craxi, Antonio, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris, Dalgard, Olav, De Knegt, Robert, De Ledinghen, Victor, Dore, Gregory, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve, Elbadri, Mohammed, El-Kassas, Mohamed, El-Sayed, Manal, Estes, Chris, Etzion, Ohad, Farag, Elmobashar, Ferradini, Laurent, Ferreira, Paulo, Flisiak, Robert, Forns, Xavier, Frankova, Sona, Fung, James, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana, Gholam, Pierre, Gish, Robert, Goleij, Pouya, Gottfredsson, Magnus, Grebely, Jason, Gschwantler, Michael, Guingane, Nanelin Alice, Hajarizadeh, Behzad, Hamid, Saeed, Hamoudi, Waseem, Harris, Aaron, Hasan, Irsan, Hatzakis, Angelos, Hellard, Margaret, Hercun, Julian, Hernandez, Javier, Hockicková, Ivana, Hsu, Yao-Chun, Hu, Ching-Chih, Husa, Petr, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jelev, Deian, Jeruma, Agita, Johannessen, Asgeir, Kåberg, Martin, Kaita, Kelly, Kaliaskarova, Kulpash, Kao, Jia-Horng, Kelly-Hanku, Angela, Khamis, Faryal, Khan, Aamir, Kheir, Omer, Khoudri, Ibtissam, Kondili, Loreta, Konysbekova, Aliya, Kristian, Pavol, Kwon, Jisoo, Lagging, Martin, Laleman, Wim, Lampertico, Pietro, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice, Lee, Mei-Hsuan, Liakina, Valentina, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham, Marinho, Rui, Mendes-Correa, Maria Cássia, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mohamed, Rosmawati, Mokhbat, Jacques, Mooneyhan, Ellen, Moreno, Christophe, Mortgat, Laure, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Naveira, Marcelo, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Ning, Qing, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin, Oguche, Stephen, Omuemu, Casimir, Ong, Janus, Opare-Sem, Ohene, Örmeci, Necati, Orrego, Mauricio, Osiowy, Carla, Papatheodoridis, George, Peck-Radosavljevic, Markus, Pessoa, Mário, Pham, Trang, Phillips, Richard, Pimenov, Nikolay, Pincay-Rodríguez, Loreley, Plaseska-Karanfilska, Dijana, Pop, Cora, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Rautiainen, Henna, Razavi-Shearer, Kathryn, Remak, William, Ribeiro, Sofia, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo, Robalino, Marcia, Roberts, Lewis, Roberts, Stuart, Rodríguez, Manuel, Roulot, Dominique, Rwegasha, John, Ryder, Stephen, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa, Salupere, Riina, Sanai, Faisal, Sanchez-Avila, Juan F, Saraswat, Vivek, Sargsyants, Narina, Sarrazin, Christoph, Sarybayeva, Gulya, Schréter, Ivan, Seguin-Devaux, Carole, Seto, Wai-Kay, Shah, Samir, Sharara, Ala, Sheikh, Mahdi, Shouval, Daniel, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta, Sinn, Dong Hyun, Sonderup, Mark, Sonneveld, Milan, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek-Siam, Tanaka, Junko, Tergast, Tammo, Terrault, Norah, Thompson, Alexander, Thompson, Peyton, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsang, Tak-Yin, Uzochukwu, Benjamin, Van Welzen, Berend, Vanwolleghem, Thomas, Vince, Adriana, Voeller, Alexis, Waheed, Yasir, Waked, Imam, Wallace, Jack, Wang, Cong, Weis, Nina, Wong, Grace, Wong, Vincent, Wu, Jaw-Ching, Yaghi, Cesar, Yesmembetov, Kakharman, Yip, Terry, Yosry, Ayman, Yu, Ming-Lung, Yuen, Man-Fung, Yurdaydin, Cihan, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie

Published
2023
Full Text
View/download PDF

5. The association between proton‐pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy.

Author

Ho, Chun‐Ting, Fu, Chia‐Chu, Tan, Elise Chia‐Hui, Kao, Wei‐Yu, Lee, Pei‐Chang, Huang, Yi‐Hsiang, Huo, Teh‐Ia, Hou, Ming‐Chih, Wu, Jaw‐Ching, and Su, Chien‐Wei

Subjects
PROPORTIONAL hazards models, CHRONIC kidney failure, CANCER prognosis, HEPATOCELLULAR carcinoma, OVERALL survival
Abstract

Background and Aim: The association between long‐term proton‐pump inhibitors (PPIs) use and malignancies had long been discussed, but it still lacks consensus. Our study investigated the association between PPI use and hepatocellular carcinoma (HCC) recurrence following curative surgery. Methods: We retrospectively enrolled 6037 patients with HCC who underwent hepatectomy. Patients were divided into four groups according to their PPI usage. (non‐users: < 28 cumulative defined daily dose [cDDD]; short‐term users: 28–89 cDDD; mid‐term users: 90–179 cDDD, and long‐term users: ≥ 180 cDDD, respectively). Recurrence‐free survival (RFS) and overall survival (OS) were analyzed using Kaplan–Meier method and Cox proportional hazard models. Results: Among the 6037 HCC patients, 2043 (33.84%) were PPI users. PPI users demonstrated better median RFS (3.10 years, interquartile range [IQR] 1.49–5.01) compared with non‐users (2.73 years, IQR 1.20–4.74; with an adjusted hazard ratio [aHR] of 0.57, 95% confidence interval [CI] 0.44–0.74, P < 0.001). When considering the cumulative dosage of PPI, only long‐term PPI users had significant lower risk of HCC recurrence than non‐PPI group (adj‐HR: 0.50; 95% CI: 0.35–0.70; P < 0.001). Moreover, the impact of long‐term PPIs use on improving RFS was significant in most of the subgroup analysis, except in patients with advanced tumor stages, with non‐cirrhosis, or with a history of chronic kidney disease. However, there were no significant differences in median OS between PPI users and non‐users (4.23 years, IQR 2.73–5.86 vs 4.04 years, IQR 2.51–5.82, P = 0.369). Conclusion: Long‐term PPI use (≥ 180 cDDD) may be associated with a better RFS in HCC patients after hepatectomy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Author

Lu, Sheng-Nan, Wang, Jing-Houng, Su, Chien-Wei, Wang, Tsang-En, Dai, Chia-Yen, Chen, Chien-Hung, Chen, Ran-Chou, Yang, Sien-Sing, Hung, Chien-Fu, Huang, Shiu-Feng, Liao, Li-Ying, Huo, The-Ia, Wu, Cheng-Chung, Lee, Po-Huang, Ting, Chin-Tsung, Lee, Wei-Chen, Chau, Gar-Yang, Wang, Chih-Chi, Lee, King-The, Huang, Yi-Hsiang, Ho, Ming-Chih, Lin, Shi-Ming, Huang, Guan-Tarn, Chen, Kuan-Yang, Lin, Xi-Zhang, Hwang, Jen-I., Chiou, Yi-You, Wang, Chung-Kwe, Hu, Jui-Ting, Chen, Shinn-Cherng, Liang, Po-Chin, Lee, Rheun-Chuan, Wu, Ding-Kwo, Lin, Cheng-Yao, Lin, Chen-Chun, Cheng, Ann-Lii, Hsu, Chiun, Chao, Yee, Chen, Li-Tzong, Wang, Po-Ming, Hong, Ji-Hong, Hsu, Hsuan-Chih, Chen, Shang-Wen, Leung, Stephen Wan, Cheng, Jason Chia-Hsien, Wu, Jaw-Ching, Wu, Chun-Ying, Hsu, Yao-Chun, Hsu, Chao-Wei, Ni, Yen-Hsuan, and Lin, Chih-Lin

Published
2018
Full Text
View/download PDF

27. Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122.

Author

Liang, Yuh‐Jin, Chiou, Yu‐Wei, Chiu, Abby Pei‐Ting, Shiao, Ming‐Shi, Teng, Wei, Lin, Chin‐Wei, Cheng, Mei‐Ling, Huang, Yen‐Hua, Liang, Kung‐Hao, Su, Chien‐Wei, Lai, Chi‐Yu, Chen, Chih‐Li, and Wu, Jaw‐Ching

Subjects
HEPATITIS B virus, METABOLIC disorders, MICRORNA, FATTY liver, VIRAL replication, HEPATOCELLULAR carcinoma
Abstract

Hepatitis B virus (HBV) hijacks autophagy for its replication. Nucleos(t)ide analogs (NUCs) treatment suppressed HBV replication and reduced hepatocellular carcinoma (HCC) incidence. However, the use of NUCs in chronic hepatitis B (CHB) patients with normal or minimally elevated serum alanine aminotransferase (ALT) levels is still debated. Animal models are crucial for studying the unanswered issue and evaluating new therapies. MicroRNA‐122 (miR‐122), which regulates fatty acid and cholesterol metabolism, is downregulated during hepatitis and HCC progression. The reciprocal inhibition of miR‐122 with HBV highlights its role in HCC development as a tumor suppressor. By crossbreeding HBV‐transgenic mice with miR‐122 knockout mice, we generated a hybrid mouse model with a high incidence of HCC up to 89% and normal ALT levels before HCC. The model exhibited early‐onset hepatic steatosis, progressive liver fibrosis, and impaired late‐phase autophagy. Metabolomics and microarray analysis identified metabolic signatures, including dysregulation of lipid metabolism, inflammation, genomic instability, the Warburg effect, reduced TCA cycle flux, energy deficiency, and impaired free radical scavenging. Antiviral treatment reduced HCC incidence in hybrid mice by approximately 30–35% compared to untreated mice. This effect was linked to the activation of ER stress‐responsive transcription factor ATF4, clearance of autophagosome cargo p62, and suppression of the CHOP‐mediated apoptosis pathway. In summary, this study suggests that despite minimal ALT elevation, HBV replication can lead to liver injury. Endoplasmic reticulum stress, reduced miR‐122 levels, mitochondrial and metabolic dysfunctions, blocking protective autophagy resulting in p62 accumulation, apoptosis, fibrosis, and HCC. Antiviral may improve the above‐mentioned pathogenesis through HBV suppression. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection

Author

Chen, Yu-Jen, primary, Su, Chien-Wei, additional, Wei, Cheng-Yi, additional, Chau, Gar-Yang, additional, Chen, Ping-Hsien, additional, Chao, Yee, additional, Huang, Yi-Hsiang, additional, Wu, Jaw-Ching, additional, Yang, Tsung-Chieh, additional, Lee, Pei-Chang, additional, and Hou, Ming-Chih, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results